以跑步疗法或抗抑郁药治疗抑郁和焦虑症患者的免疫代谢性抑郁症：对 MOTAR 研究的二次分析。

IF 8.8 2区医学 Q1 IMMUNOLOGY

Brain, Behavior, and Immunity Pub Date : 2024-10-28 DOI:10.1016/j.bbi.2024.10.033

Sarah R. Vreijling , Brenda W.J.H. Penninx , Josine E. Verhoeven , Charlotte E. Teunissen , Elena R. Blujdea , Aartjan T.F. Beekman , Femke Lamers , Rick Jansen

{"title":"以跑步疗法或抗抑郁药治疗抑郁和焦虑症患者的免疫代谢性抑郁症：对 MOTAR 研究的二次分析。","authors":"Sarah R. Vreijling , Brenda W.J.H. Penninx , Josine E. Verhoeven , Charlotte E. Teunissen , Elena R. Blujdea , Aartjan T.F. Beekman , Femke Lamers , Rick Jansen","doi":"10.1016/j.bbi.2024.10.033","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.</div></div><div><h3>Methods</h3><div>Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.</div></div><div><h3>Results</h3><div>Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.</div></div><div><h3>Conclusions</h3><div>This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.</div></div><div><h3>Trial registration</h3><div><span><span>Trialregister.nl</span><svg><path></path></svg></span> Number of identification: NTR3460.</div></div>","PeriodicalId":9199,"journal":{"name":"Brain, Behavior, and Immunity","volume":"123 ","pages":"Pages 876-883"},"PeriodicalIF":8.8000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study\",\"authors\":\"Sarah R. Vreijling , Brenda W.J.H. Penninx , Josine E. Verhoeven , Charlotte E. Teunissen , Elena R. Blujdea , Aartjan T.F. Beekman , Femke Lamers , Rick Jansen\",\"doi\":\"10.1016/j.bbi.2024.10.033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.</div></div><div><h3>Methods</h3><div>Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.</div></div><div><h3>Results</h3><div>Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.</div></div><div><h3>Conclusions</h3><div>This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.</div></div><div><h3>Trial registration</h3><div><span><span>Trialregister.nl</span><svg><path></path></svg></span> Number of identification: NTR3460.</div></div>\",\"PeriodicalId\":9199,\"journal\":{\"name\":\"Brain, Behavior, and Immunity\",\"volume\":\"123 \",\"pages\":\"Pages 876-883\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain, Behavior, and Immunity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0889159124006731\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, Behavior, and Immunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889159124006731","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：运动能促进免疫代谢健康，并逐渐被认为是一种有效的抑郁症治疗方法。运动可能对免疫代谢性抑郁症（IMD）患者有益，因为这些患者会出现炎症和代谢失调，对抗抑郁药的反应较小。这项对 MOTAR 研究的二次分析比较了跑步疗法和抗抑郁药对抑郁症和/或焦虑症患者 IMD 特征的影响。此外，我们还评估了基线IMD是否会调节干预对抑郁症的影响：在部分随机的患者偏好设计中，参与者接受了为期 16 周的集体跑步治疗（96 人）或艾司西酞普兰/舍曲林（45 人）。IMD特征包括非典型、能量相关症状（AES）严重程度、炎症指数（CRP、INF-γ、IL-6、TNF-α）、代谢综合征指数、三种代谢物原理成分（PC）（由73种代谢物得出）和综合IMD指数：结果：干预措施对代谢综合征指数（d = 0.59，p = 0.026）和 IMD 指数（d = 0.85，p 结论：干预措施对代谢综合征指数（d = 0.59，p = 0.026）和 IMD 指数（d = 0.85，p = 0.026）的影响不同：本研究表明，运动比抗抑郁药更有效地针对 IMD 维度。就抑郁症的缓解而言，IMD 患者从跑步治疗中获益并不比抗抑郁药物多。运动应被视为一种替代或辅助治疗方法，尤其是在减少抑郁症患者的IMD特征方面：试验注册：Trialregister.nl 编号：NTR3460：NTR3460.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study

Background

Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.

Methods

Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.

Results

Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.

Conclusions

This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.

Trial registration

Trialregister.nl Number of identification: NTR3460.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brain, Behavior, and Immunity 医学-免疫学

CiteScore

29.60

自引率

2.00%

发文量

290

审稿时长

28 days

期刊介绍： Established in 1987, Brain, Behavior, and Immunity proudly serves as the official journal of the Psychoneuroimmunology Research Society (PNIRS). This pioneering journal is dedicated to publishing peer-reviewed basic, experimental, and clinical studies that explore the intricate interactions among behavioral, neural, endocrine, and immune systems in both humans and animals. As an international and interdisciplinary platform, Brain, Behavior, and Immunity focuses on original research spanning neuroscience, immunology, integrative physiology, behavioral biology, psychiatry, psychology, and clinical medicine. The journal is inclusive of research conducted at various levels, including molecular, cellular, social, and whole organism perspectives. With a commitment to efficiency, the journal facilitates online submission and review, ensuring timely publication of experimental results. Manuscripts typically undergo peer review and are returned to authors within 30 days of submission. It's worth noting that Brain, Behavior, and Immunity, published eight times a year, does not impose submission fees or page charges, fostering an open and accessible platform for scientific discourse.